When serial entrepreneur Barak Azmon started his first ophthalmic technology company in 2000, it was one of just a few medical device companies in Israel occupying the space. Now, nearly two decades later, he says the ophthalmology sector in the country has grown to encompass more than 60 companies.
Israel's Vision For The Future: Investors Open Eyes To Ophthalmology
As the global population ages, the demand for ophthalmic devices is expected to rise significantly. Medtech Insight meets with some of Israel's industry leaders who are developing cutting-edge technologies to address the ever-growing ophthalmic market.
More from Ophthalmology
• By
Barcelona-based accelerator S2 Xpeed is driving the rapid growth of medtech and hardware start-ups in Europe. Operating under a "sweat equity" model, the program helps early-stage companies move from prototype to manufacturing readiness in exchange for equity. This month, the accelerator will add a fourth cohort of 10 more start-ups, five of which are in the medtech space.
Seonix Bio’s Newly Launched Saliva-Based Genetic Test Aims To Shed Light On Glaucoma Risk Assessment
• By
Seonix launched SightScore, the first clinical polygenic risk score test for glaucoma available in the US, and plans to introduce more genetic-based tests for eye conditions such as macular degeneration.
• By
The US FDA released six more device classifications in early September, including products from Edwards, Interscope, and Baxter Healthcare.
• By
The program, which brings together innovators and device industry stakeholders, helps ease the path to market for novel devices.
More from Device Area
• By
Abbott presented late-breaking data at the 2025 American College of Cardiology conference demonstrating that TriClip transcatheter edge-to-edge repair offers prolonged patient benefits compared to medical treatment alone after two years, which were not evident at one year.
• By
The Cologuard Plus test has a sensitivity of 95% and a specificity of 94% for the detection of colorectal cancer; “unmatched accuracy,” according to Exact Sciences.
• By
The Visby Medical Women’s Sexual Health Test is the first over-the-counter test cleared by the US Food and Drug Administration to detect chlamydia, gonorrhea and trichomoniasis. It delivers results in about 30 minutes.